Valsartan is used clinical for receptor antagonist of angiotensin AT1, has good effect to the different degree of hypertension patients who used other antihypertensive without efficacy , is a new generation of highly efficient antihypertensive .
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium.
Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.
Valsartan is an angiotensin II receptor antagonistwith particularly high affinity for the type I (AT1) angiotensin receptor. By blocking the action of angiotensin, valsartan dilates blood vessels and reduces blood pressure. In the U.S., valsartan is indicated for treatment of high blood pressure, congestive heart failure (CHF), or post-myocardial infarction (MI) .
Çuňňur hyzmatdaşlygy bolan ýokary hilli önümler we bäsdeşlik bahalary bilen üpjün edip biljek köp sanly ýokary hilli zawodlarymyz bar. Şeýle hem, köpçülikleýin satyn almak üçin arzanladyş berip bileris. Köp hünärli ýük ekspeditor kompaniýalary bilen hyzmatdaşlyk edýäris, önümleri ygtybarly we rahat eliňize berip bileris. Eltip beriş wagty, töleg tassyklanandan 3-20 gün soň.
Haryt | Test Standard | Testing Result | |
Daş görnüşi | Powder | Jogap berýär | |
Color | Ak poroşok | Jogap berýär | |
Particle Size | 100% pass 80 mesh | Jogap berýär | |
Oder | Characteristic | Jogap berýär | |
Taste | Characteristic | Jogap berýär | |
Guramakda ýitgi | ≤5.0% | 2.20% | |
Residue on Ignition | ≤0.1% | 0.05% | |
Residual acetone | ≤0.1% | Jogap berýär | |
Residual Ethanol | ≤0.5% | Jogap berýär | |
Heave Mentals | ≤10ppm | Jogap berýär | |
Na | ≤0.1% | <0.1% | |
Sah | ≤3 ppm | Jogap berýär | |
Jemi tabak | <1000CFU/g | Jogap berýär | |
Yeast & Mold | <100 CFU /g | Jogap berýär | |
E. Coli | Ativearamaz | Jogap berýär | |
Salmonella | Ativearamaz | Jogap berýär | |
Conclusion: Conform with USP Standard |
1. Siz zawodmy ýa-da söwda kompaniýasymy?
Biz bir bitewi hyzmaty hödürleýän senagaty we söwdany birleşdirýän birleşdiriji. OEM kabul edilip bilner.
2. Nusga berýärsiňizmi? Mugtmy ýa-da goşmaça?
Mugt nusgalar. Nusganyň ýük tölegini siziň tarapyňyz tölemeli.
3. Hil gözegçiligi bilen baglanyşykly şahadatnamalaryňyz barmy?
Hilini üpjün etmek üçin ISO 9001: 2008 kepilnamasy.
4. Sitata almak üçin näme bermeli?
Size zerur önümiň görnüşi, sargyt mukdary, salgysy we aýratyn talaplary barada habar beriň. Sitata salgylanma üçin wagtynda berler.
5. Haýsy töleg usulyny has gowy görýärsiňiz? Haýsy şertler kabul edilýär?
Kabul edilen gowşuryş şertleri: FOB, CFR, CIF, EXW;
Kabul edilen töleg walýutasy: USD;
Accepted Payment Type: T/T,Western Union; Paypal,BTC
Gepleşik dili: Iňlis.
Önüm kategoriýalary